We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Building Better Vaccines for SARS-CoV-2
News

Building Better Vaccines for SARS-CoV-2

Building Better Vaccines for SARS-CoV-2
News

Building Better Vaccines for SARS-CoV-2

Credit: fernando zhiminaicela/ Pixabay
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Building Better Vaccines for SARS-CoV-2"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Previous research has shown that the spike (S) protein of -CoV-2 binds to a host cell receptor, facilitating viral entry. Research has also shown that SARS-CoV-2 variants that lose the furin cleavage site at the spike protein (S gene mutants) emerge rapidly during propagation in Vero cells (lineage of cells used in cell cultures). 

Now, new research published in mBio, an open-access journal of the American Society for Microbiology, shows that hamsters inoculated with S gene mutants show resistance to subsequent infection with both the parental strain and the currently emerging SARS-CoV-2 alpha and gamma variants (B.1.1.7 variant, first identified in the U.K. and P.1. variant, first identified in Brazil, respectively). The research highlights the potential benefits of S gene mutants as immunogens (antigens that can trigger an immune response). 

“SARS-CoV-2 S gene mutants may be used as immunogens for live-attenuated vaccines, similar to the current yellow fever vaccine,” said Hirofumi Sawa, Ph.D., M.D., study principal investigator in the Division of Molecular Pathobiology, International Institute for Zoonosis Control, at Hokkaido University, in Sapporo Japan, and with One Health Research Center at Hokkaido University.   

In the new study, researchers set out to further characterize SARS-CoV-2 S gene mutants properties through animal experiments using hamsters. All infected animals were maintained in isolators at the biosafety level-3 facility. “Our experiments were conducted in accordance with set guidelines. Because we had to move animals with the isolators into the safety cabinet to monitor the animals, we did a lot of heavy lifting on a daily basis,” said lead study author Michihito Sasaki, Ph.D., D.V.M., a lecturer in the Division of Molecular Pathobiology, International Institute for Zoonosis Control, at Hokkaido University. 

The researchers found that the SARS-CoV-2 S gene mutants are weakened variants but can induce protective immunity against infection with clinical strains of SARS-CoV-2. “Because these variants rapidly emerge through SARS-CoV-2 propagation in some cell lines, including Vero cells, researchers should be alert to the possibility of unexpected contamination with these variants,” said Dr. Sasaki. 

The researchers say their next steps are to uncover the mechanism of severe COVID-19 and develop new therapeutic strategies for COVID-19. “To overcome the COVID-19 pandemic, a multisectoral and transdisciplinary approach under the ‘One Health’ umbrella is needed,” said Dr. Sawa. “At our International Institute for Zoonosis Control, we endeavor to establish effective strategies for prediction, prevention and control of zoonotic diseases, including COVID-19.” 

Reference: Sasaki M, Toba S, Itakura Y, et al. SARS-CoV-2 bearing a mutation at the S1/S2 cleavage site exhibits attenuated virulence and confers protective immunity. mBio. 0(0):e01415-21. doi: 10.1128/mBio.01415-21

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement